Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could stop deadly clots in cancer patients

NCT ID NCT07410117

Prevention Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 6 times

Summary

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks for side effects like bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
REGN7508 (cenvacibart), a monoclonal antibody
What this could lead to
If successful, this could provide a new way to prevent dangerous blood clots in people with cancer, reducing the risk of stroke or death.
What could go wrong
This is still experimental. The drug may not work better than placebo, and there is a risk of bleeding or other side effects. Results are not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Has a histologically confirmed diagnosis of malignant solid tumors which are locally advanced or metastatic as described in the protocol 2. Has a Khorana thromboembolic risk score ≥2 during screening period or harbors a somatic documented tumor genetic variant known to be associated with a similar increased risk of VTE as described in the protocol 3. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 at the time of screening and day 1 prior to the first dose of study intervention Key Exclusion Criteria: 1. Has known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy) 2. Has a cancer diagnosis consisting solely of basal cell or squamous cell skin carcinoma 3. Has a primary brain tumor or brain metastases as described in the protocol 4. Has proximal lower extremity DVT locally detected by Compression Ultrasound (CUS) during screening period 5. Has any condition that, as judged by the investigator, may confound the results of the study or would place the participant at increased risk of harm if he/she participated in the study Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer-associated thrombosis (CAT) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hemorrhage neoplasm pulmonary embolism venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer-associated thrombosis (CAT)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • American Hospital Tbilisi

    RECRUITING

    Tbilisi, 0102, Georgia

  • Bioresearch Partner- Hialeah Hospital

    RECRUITING

    Hialeah, Florida, 33013, United States

  • Caucasus Medical Centre

    RECRUITING

    Tbilisi, 0186, Georgia

  • El Paso Medical Research Institute (Medresearch Inc)

    RECRUITING

    El Paso, Texas, 79902, United States

  • Helios Clinical Research

    RECRUITING

    North Miami Beach, Florida, 33169, United States

  • Hyogo Cancer Center - Gastroenterology Department

    RECRUITING

    Akashi, Hyōgo, 673-8558, Japan

  • Institute of Clinical Oncology

    RECRUITING

    Tbilisi, 0159, Georgia

  • JSC Evex Hospitals - Caraps Medline

    RECRUITING

    Tbilisi, 0179, Georgia

  • Kagawa University Hospital

    RECRUITING

    Kita-gun, Kagawa-ken, 761-0793, Japan

  • Krystyna Kiel Oncology Center

    RECRUITING

    Kutaisi, Imereti, 4600, Georgia

  • LTD Cancer Research Centre

    RECRUITING

    Tbilisi, 0179, Georgia

  • LTD High Technology Hospital Medcenter

    RECRUITING

    Batumi, Adjara, 6000, Georgia

  • Llc Todua Clinic

    RECRUITING

    Tbilisi, 0112, Georgia

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10021, United States

  • National Hospital Organization Osaka National Hospital (ONH)

    RECRUITING

    Chuo, Osaka, 540-0006, Japan

  • Niigata University Medical & Dental Hospital

    RECRUITING

    Niigata, 951-8520, Japan

  • Saitama Cancer Center

    RECRUITING

    Kitaadachigun, Saitama, 362-0806, Japan

  • Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic

    RECRUITING

    Tbilisi, 0144, Georgia

  • Tokai University Hospital

    RECRUITING

    Isehara-Shi, Kanagawa, 259-1193, Japan

  • Yamaguchi University Hospital

    RECRUITING

    Ube, Yamaguchi, 755-8505, Japan